Evidence map›Paper›PMID 40236833›Full record

ArticleComputational and structural biotechnology journal2025

MACRAMÉ - Advanced characterisation methodologies to assess and predict the health and environmental risks of advanced materials.

Steffi Friedrichs, Christian Seitz, Eric Bleeker, Rob Vandebriel, Samia Ouhajji, Evert Duistermaat, Martin Wiemann, Antje Vennemann, Alberto Katsumiti, Tina Buerki-Thurnherr and 14 more

Abstract read
In one paragraph

Article in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. ARACRA: Automated RNA-seq Analysis for Chemical Risk Assessment.Computational and structural biotechnology journal · 2026
    Article
  2. Article
  3. Article
  4. Setting off on the right path: make your research regulatory relevant.Frontiers in research metrics and analytics · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Steffi FriedrichsAcumenIST SRL, Rue Fétis 19, Etterbeek 1040, Belgium.
Christian SeitzAcumenIST SRL, Werderstrasse 36, Heidelberg 69120, Germany.
Eric BleekerNetherlands National Institute for Public Health and the Environment - RIVM, Antonie van Leeuwenhoeklaan 9, Bilthoven 3721 MA, the Netherlands.
Rob VandebrielNetherlands National Institute for Public Health and the Environment - RIVM, Antonie van Leeuwenhoeklaan 9, Bilthoven 3721 MA, the Netherlands.
Samia OuhajjiNetherlands National Institute for Public Health and the Environment - RIVM, Antonie van Leeuwenhoeklaan 9, Bilthoven 3721 MA, the Netherlands.
Evert DuistermaatNetherlands National Institute for Public Health and the Environment - RIVM, Antonie van Leeuwenhoeklaan 9, Bilthoven 3721 MA, the Netherlands.
Martin WiemannIBE R&D Institute for Lung Health gGmbH, Mendelstr. 11, Münster 48149, Germany.
Antje VennemannIBE R&D Institute for Lung Health gGmbH, Mendelstr. 11, Münster 48149, Germany.
Alberto KatsumitiGAIKER Technology Centre, Parque Tecnológico, edif. 202, Zamudio 48170, Spain.
Tina Buerki-ThurnherrSwiss Federal Laboratories for Materials Science and Technology (Empa), Lerchenfeldstrasse 5, St.Gallen 9014, Switzerland.
Govind GuptaSwiss Federal Laboratories for Materials Science and Technology (Empa), Lerchenfeldstrasse 5, St.Gallen 9014, Switzerland.
Peter WickSwiss Federal Laboratories for Materials Science and Technology (Empa), Lerchenfeldstrasse 5, St.Gallen 9014, Switzerland.
Luis Mauricio Ortiz-GalvezSwiss Federal Laboratories for Materials Science and Technology (Empa), Lerchenfeldstrasse 5, St.Gallen 9014, Switzerland.
Jimeng WuSwiss Federal Laboratories for Materials Science and Technology (Empa), Lerchenfeldstrasse 5, St.Gallen 9014, Switzerland.
Klaus-Michael WeltringGesellschaft für Bioanalytik Münster e. V., Mendelstraße 17, Münster 48149, Germany.
Daniel HaaseGesellschaft für Bioanalytik Münster e. V., Mendelstraße 17, Münster 48149, Germany.
Elisabeth HeunischBundesanstalt für Arbeitsschutz und Arbeitsmedizin (BAuA), Nöldnerstraße 40 - 42, Berlin 10317, Germany.
Anna PohlBundesanstalt für Arbeitsschutz und Arbeitsmedizin (BAuA), Nöldnerstraße 40 - 42, Berlin 10317, Germany.
Katie ReillySchool of Geography, Earth and Environmental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom.
Zhiling GuoSchool of Geography, Earth and Environmental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom.
Iseult LynchSchool of Geography, Earth and Environmental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom.
Thomas ExnerSeven Past Nine d.o.o., Hribljane 10, Cerknica 1380, Slovenia.
Birgit HagenhoffTascon GmbH, Mendelstr. 17, Münster 48149, Germany.
Daniel BreitensteinTascon GmbH, Mendelstr. 17, Münster 48149, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ensuring the safety and sustainability of advanced materials (AdMas) is critical for fostering innovation while protecting human health and the environment. As industries integrate AdMas into commercial products to innovate in the next stage of the value chains, there is an urgent need for robust methodologies to detect, characterize, and assess their potential risks throughout their life cycle. The MACRAMÉ Project addresses this challenge by advancing standardized testing and regulatory frameworks, supporting the EU's vision for a toxic-free environment. Through cutting-edge research and international collaboration, MACRAMÉ lays the groundwork for reliable hazard assessment, regulatory compliance, and the responsible development of next-generation materials. The MACRAMÉ Project aims to enhance the detection, characterization, and quantification of Advanced Materials (AdMas) throughout their life cycle, assessing potential human and environmental health impacts during exposure. By developing, demonstrating, and standardizing advanced methodologies, MACRAMÉ ensures their broad applicability across market-relevant AdMas-containing products. Fully aligned with EU strategies such as the Chemical Strategy for Sustainability and the European Green Deal, the project extends nanosafety approaches to the broader AdMas category, focusing on inhalable carbon-based materials - graphene-related materials, carbon nanofibers, and poly lactic-co-glycolic acid nanoparticles. Building on over 15 years of research, MACRAMÉ integrates knowledge from major European and international initiatives to establish harmonized test guidelines, guidance documents, and standards. Through five industrial Use-Cases, the project applies innovative sample preparation, detection, and toxicity assessment techniques to develop a tiered approach for AdMa safety testing. Centralized in the MACRAMÉ Information Hub, all data will support regulatory frameworks and future research. The project's outcomes - harmonization and pre-standardization proposals - will contribute to a unified European assessment framework, reinforcing the continent's leadership in safe and sustainable materials innovation.

Indexed as

Advanced characterisation techniquesAdvanced materialsHarmonisation and pre-standardisationHarmonisation of test methodsHazard, toxicity, and eco-toxicity testingLife cycle exposure(meta) data managementSafe and sustainable-by-designTest method development

Identifiers

PMID40236833
PMCPMC11997261

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.